Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
3.0
Journals
JPM
Special Issues
Precision Medicine in Neurology
share announcement

Precision Medicine in Neurology

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: closed (11 October 2024) | Viewed by 2474

Special Issue Editors

Prof. Dr. Corneliu Toader

E-Mail Website
Guest Editor
1. Department of Neurosurgery, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
2. Department of Vascular Neurosurgery, National Institute of Neurology and Neurovascular Diseases, 077160 Bucharest, Romania
Interests: neurosurgery; neurology; neurovascular pathology; neuro-oncology; cognitive science
Prof. Dr. Alexandru Vladimir Ciurea

E-Mail Website
Guest Editor
1. Department of Neurosurgery, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
2. Department of Neurosurgery and Scientific Director at the Sanador Clinical Hospital, 70000 Bucharest, Romania
3. Medical Section within the Romanian Academy, 010071 Bucharest, Romania
Interests: neurosurgery; high-grade gliomas; tumoral surgery; pediatric neurosurgery; neuro-oncology; neurosciences; neurovascular pathology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Precision medicine represents a transformative approach to healthcare, customizing patient care to an individual’s genetic makeup, lifestyle and environment. In the field of neurology, this paradigm shift promises to revolutionize the diagnosis, treatment and management of neurological disorders, which are among the most complex and challenging areas of medicine. The significance of precision medicine in neurology cannot be overstated given the vast heterogeneity and intricacy of neurological diseases, ranging from neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease to neuroinflammatory disorders such as multiple sclerosis.

The aim of the Special Issue is to assemble a comprehensive collection of original research articles, reviews and case studies that illuminate the forefront of precision medicine as it applies to the field of neurology. This endeavor aligns with the journal’s scope, which emphasizes innovative research and advancements in medical science. The focus of this Special Issue is meticulously designed to fit within the journal’s aims and scope by addressing a critical and emerging area of neurology that promises to redefine patient care through the application of genetic, molecular and environmental insights to develop highly individualized treatment strategies. The Special Issue intends to curate a minimum of 10 articles, ensuring diverse perspectives and findings that collectively advance our understanding and application of precision medicine in neurology. This collection of articles will not only serve as a valuable resource for researchers and clinicians, but also potentially provide the basis for a printed book edition, offering a tangible reference for the ongoing evolution of personalized neurological care.

We cordially invite contributions from researchers and clinicians to our Special Issue, focusing on a broad spectrum of neurological disorders.

Prof. Dr. Corneliu Toader
Prof. Dr. Alexandru Vladimir Ciurea
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision medicine
  • neurological disorders
  • genomics
  • epigenomics
  • biomarkers
  • personalized therapy
  • disease progression
  • immunological interactions
  • neurological disease microenvironment
  • innovative diagnostic technologies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

13 pages, 293 KiB  
Review
Considering Biomarkers of Neurodegeneration in Alzheimer’s Disease: The Potential of Circulating Cell-Free DNA in Precision Neurology
by Chad A. Pollard, Erin R. Saito, Jeffrey M. Burns, Jonathon T. Hill and Timothy G. Jenkins
J. Pers. Med. 2024, 14(11), 1104; https://doi.org/10.3390/jpm14111104 - 13 Nov 2024
Viewed by 761
Abstract
Neurodegenerative diseases, such as Alzheimer’s disease (AD), are a growing public health crisis, exacerbated by an aging global population and the lack of effective early disease-modifying therapies. Early detection of neurodegenerative disorders is critical to delaying symptom onset and mitigating disease progression, but [...] Read more.
Neurodegenerative diseases, such as Alzheimer’s disease (AD), are a growing public health crisis, exacerbated by an aging global population and the lack of effective early disease-modifying therapies. Early detection of neurodegenerative disorders is critical to delaying symptom onset and mitigating disease progression, but current diagnostic tools often rely on detecting pathology once clinical symptoms have emerged and significant neuronal damage has already occurred. While disease-specific biomarkers, such as amyloid-beta and tau in AD, offer precise insights, they are too limited in scope for broader neurodegeneration screening for these conditions. Conversely, general biomarkers like neurofilament light chain (NfL) provide valuable staging information but lack targeted insights. Circulating cell-free DNA (cfDNA), released during cell death, is emerging as a promising biomarker for early detection. Derived from dying cells, cfDNA can capture both general neurodegenerative signals and disease-specific insights, offering multi-layered genomic and epigenomic information. Though its clinical potential remains under investigation, advances in cfDNA detection sensitivity, standardized protocols, and reference ranges could establish cfDNA as a valuable tool for early screening. cfDNA methylation signatures, in particular, show great promise for identifying tissue-of-origin and disease-specific changes, offering a minimally invasive biomarker that could transform precision neurology. However, further research is required to address technological challenges and validate cfDNA’s utility in clinical settings. Here, we review recent work assessing cfDNA as a potential early biomarker in AD. With continued advances, cfDNA could play a pivotal role in shifting care from reactive to proactive, improving diagnostic timelines and patient outcomes. Full article
(This article belongs to the Special Issue Precision Medicine in Neurology)
25 pages, 620 KiB  
Review
Biomarkers and Rehabilitation for Functional Neurological Disorder
by Victor W. Mark
J. Pers. Med. 2024, 14(9), 948; https://doi.org/10.3390/jpm14090948 - 7 Sep 2024
Viewed by 1296
Abstract
Functional neurological disorder, or FND, is widely misunderstood, particularly when considering recent research indicating that the illness has numerous biological markers in addition to its psychiatric disorder associations. Nonetheless, the long-held view that FND is a mental illness without a biological basis, or [...] Read more.
Functional neurological disorder, or FND, is widely misunderstood, particularly when considering recent research indicating that the illness has numerous biological markers in addition to its psychiatric disorder associations. Nonetheless, the long-held view that FND is a mental illness without a biological basis, or even a contrived (malingered) illness, remains pervasive both in current medical care and general society. This is because FND involves intermittent disability that rapidly and involuntarily alternates with improved neurological control. This has in turn caused shaming, perceived low self-efficacy, and social isolation for the patients. Until now, biomarker reviews for FND tended not to examine the features that are shared with canonical neurological disorders. This review, in contrast, examines current research on FND biomarkers, and in particular their overlap with canonical neurological disorders, along with the encouraging outcomes for numerous physical rehabilitation trials for FND. These findings support the perspective endorsed here that FND is unquestionably a neurological disorder that is also associated with many biological markers that lie outside of the central nervous system. These results suggest that FND entails multiple biological abnormalities that are widely distributed in the body. General healthcare providers would benefit their care for their patients through their improved understanding of the illness and recourses for support and treatment that are provided in this review. Full article
(This article belongs to the Special Issue Precision Medicine in Neurology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop